Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression.
RDoC Constructs
Research domain criteria
antidepressant
behavioral paradigm
drug targets
major depressive disorder
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
07
2020
revised:
27
10
2020
accepted:
03
11
2020
pubmed:
6
1
2021
medline:
17
8
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction. A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed. In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects. The RDoC framework may facilitate a more specific use of antidepressants based on the individual's spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction.
METHODS
METHODS
A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed.
DISCUSSION
CONCLUSIONS
In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects.
CONCLUSION
CONCLUSIONS
The RDoC framework may facilitate a more specific use of antidepressants based on the individual's spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
Identifiants
pubmed: 33397226
pii: CMC-EPUB-112993
doi: 10.2174/0929867328666210104104938
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4296-4320Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.